Cargando…
Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator
BACKGROUND: Patients with cardiac sarcoidosis are at increased risk of ventricular tachycardia/fibrillation. OBJECTIVE: We tested the hypothesis that the wearable cardioverter defibrillator can be used to mitigate the risk of sudden cardiac death among cardiac sarcoidosis patients. METHODS: A retros...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864098/ https://www.ncbi.nlm.nih.gov/pubmed/29566033 http://dx.doi.org/10.1371/journal.pone.0194496 |
_version_ | 1783308493777797120 |
---|---|
author | Skowasch, Dirk Ringquist, Steven Nickenig, Georg Andrié, René |
author_facet | Skowasch, Dirk Ringquist, Steven Nickenig, Georg Andrié, René |
author_sort | Skowasch, Dirk |
collection | PubMed |
description | BACKGROUND: Patients with cardiac sarcoidosis are at increased risk of ventricular tachycardia/fibrillation. OBJECTIVE: We tested the hypothesis that the wearable cardioverter defibrillator can be used to mitigate the risk of sudden cardiac death among cardiac sarcoidosis patients. METHODS: A retrospective review of the commercial database identified cardiac sarcoidosis patients who wore the wearable cardioverter defibrillator. Evidence for cardiac sarcoidosis diagnosis as well as demographic, co-morbidity and left ventricular ejection fraction were provided by patient clinical records. Clinical data also included daily wearable cardioverter defibrillator wear, shock treatment and survival information. RESULTS: The wearable cardioverter defibrillator was worn by 46 cardiac sarcoidosis patients, 24 (52%) male. The median age was 48 years and median left ventricular ejection fraction was 30%. The wearable cardioverter defibrillator was worn a median of 23.6 hours each day. There were 11 ventricular tachycardia/fibrillation episodes occurring in 10 (22%) patients. Ventricular tachycardia/fibrillation occurred over a range of 1 to 79 days, median 24 days. First-shock success for conversion of ventricular tachycardia/fibrillation was 100%. Patient survival 24 hours after shock treatment was 100%. Follow up to determine the reason for discontinuing wearable cardioverter defibrillator use indicated that among shocked patients 7 received an implantable cardioverter defibrillator, 1 patient was admitted to the hospital ending in death 2 weeks after discontinuing wearable cardioverter defibrillator use, and 2 patients were lost to follow up. Among the not shocked patients, there were 16 who received an implantable cardioverter defibrillator while 7 achieved improved left ventricular ejection fraction. CONCLUSION: Management of sudden cardiac death among cardiac sarcoidosis patients was aided by the wearable cardioverter defibrillator resulting in successful termination of ventricular tachycardia/fibrillation upon delivery of shock. |
format | Online Article Text |
id | pubmed-5864098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-58640982018-03-28 Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator Skowasch, Dirk Ringquist, Steven Nickenig, Georg Andrié, René PLoS One Research Article BACKGROUND: Patients with cardiac sarcoidosis are at increased risk of ventricular tachycardia/fibrillation. OBJECTIVE: We tested the hypothesis that the wearable cardioverter defibrillator can be used to mitigate the risk of sudden cardiac death among cardiac sarcoidosis patients. METHODS: A retrospective review of the commercial database identified cardiac sarcoidosis patients who wore the wearable cardioverter defibrillator. Evidence for cardiac sarcoidosis diagnosis as well as demographic, co-morbidity and left ventricular ejection fraction were provided by patient clinical records. Clinical data also included daily wearable cardioverter defibrillator wear, shock treatment and survival information. RESULTS: The wearable cardioverter defibrillator was worn by 46 cardiac sarcoidosis patients, 24 (52%) male. The median age was 48 years and median left ventricular ejection fraction was 30%. The wearable cardioverter defibrillator was worn a median of 23.6 hours each day. There were 11 ventricular tachycardia/fibrillation episodes occurring in 10 (22%) patients. Ventricular tachycardia/fibrillation occurred over a range of 1 to 79 days, median 24 days. First-shock success for conversion of ventricular tachycardia/fibrillation was 100%. Patient survival 24 hours after shock treatment was 100%. Follow up to determine the reason for discontinuing wearable cardioverter defibrillator use indicated that among shocked patients 7 received an implantable cardioverter defibrillator, 1 patient was admitted to the hospital ending in death 2 weeks after discontinuing wearable cardioverter defibrillator use, and 2 patients were lost to follow up. Among the not shocked patients, there were 16 who received an implantable cardioverter defibrillator while 7 achieved improved left ventricular ejection fraction. CONCLUSION: Management of sudden cardiac death among cardiac sarcoidosis patients was aided by the wearable cardioverter defibrillator resulting in successful termination of ventricular tachycardia/fibrillation upon delivery of shock. Public Library of Science 2018-03-22 /pmc/articles/PMC5864098/ /pubmed/29566033 http://dx.doi.org/10.1371/journal.pone.0194496 Text en © 2018 Skowasch et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Skowasch, Dirk Ringquist, Steven Nickenig, Georg Andrié, René Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
title | Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
title_full | Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
title_fullStr | Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
title_full_unstemmed | Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
title_short | Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
title_sort | management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864098/ https://www.ncbi.nlm.nih.gov/pubmed/29566033 http://dx.doi.org/10.1371/journal.pone.0194496 |
work_keys_str_mv | AT skowaschdirk managementofsuddencardiacdeathincardiacsarcoidosisusingthewearablecardioverterdefibrillator AT ringquiststeven managementofsuddencardiacdeathincardiacsarcoidosisusingthewearablecardioverterdefibrillator AT nickeniggeorg managementofsuddencardiacdeathincardiacsarcoidosisusingthewearablecardioverterdefibrillator AT andrierene managementofsuddencardiacdeathincardiacsarcoidosisusingthewearablecardioverterdefibrillator |